Kiniksa(KNSA) ZACKS·2025-04-29 13:36Core Viewpoint - Kiniksa Pharmaceuticals reported a quarterly earnings of $0.11 per share, significantly exceeding the Zacks Consensus Estimate of $0.02 per share, and showing a substantial improvement from a loss of $0.25 per share a year ago, indicating a strong earnings surprise of 450% [1] Financial Performance - The company achieved revenues of $137.79 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 7.35%, and reflecting a year-over-year increase from $79.86 million [2] - Over the last four quarters, Kiniksa Pharmaceuticals has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance - Kiniksa Pharmaceuticals shares have increased approximately 8.5% since the beginning of the year, contrasting with a decline of -6% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $138.46 million, and for the current fiscal year, it is $0.59 on revenues of $571.35 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Kiniksa Pharmaceuticals belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook as the top 50% of Zacks-ranked industries tend to outperform the bottom 50% by more than 2 to 1 [8]